Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease

2020829 citationsJournal Articlebronze Open Access

Authors

Robert Zeiser · University of Freiburg

Nikolas von Bubnoff · University of Lübeck

Jason Butler · Royal Brisbane and Women's Hospital

Mohamad Mohty

Dietger Niederwieser

Reuven Or

Jeff Szer · Peter MacCallum Cancer Centre

Eva Wagner · University Medical Center of the Johannes Gutenberg University Mainz

Abstract

Among patients with glucocorticoid-refractory or -dependent chronic GVHD, ruxolitinib led to significantly greater overall response, failure-free survival, and symptom response. The incidence of thrombocytopenia and anemia was greater with ruxolitinib. (Funded by Novartis and Incyte; REACH3 ClinicalTrials.gov number, NCT03112603.).

Topics & Keywords

Hematopoietic Stem Cell Transplantation Immune Cell Function and Interaction T-cell and B-cell Immunology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 382, Issue 19, pp. 1800-1810

DOI: 10.1056/nejmoa1917635

Field-Weighted Citation Impact: 61.54